Marker Therapeutics, Inc. (MRKR) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Marker Therapeutics, Inc. (MRKR) Earnings Overview
As of June 23, 2026, Marker Therapeutics, Inc. (MRKR) reported trailing twelve-month net income of -$11M, reflecting +33.6% year-over-year growth. The company earned $-0.56 per diluted share over the past four quarters.
Looking at the long-term picture, MRKR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$385,000 in fiscal 2001.
Marker Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), AGEN ($65M net income, 0.1% margin), ADCT (-$137M net income, -175.3% margin), MRKR has comparable earnings metrics. Compare MRKR vs FATE →
MRKR Earnings vs Peers
Earnings metrics vs comparable public companies
MRKR Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | -13.3% | -$13M | $-0.79 | - | - |
| 2024 | -$11M | -30.3% | -$11M | $-1.19 | -162.8% | -168.7% |
| 2023 | -$8M | +72.5% | -$15M | $-1.93 | -248.8% | -440.4% |
| 2022 | -$30M | +28.5% | -$20M | $-3.58 | -851.9% | -563.3% |
| 2021 | -$42M | -45.9% | -$39M | $-5.47 | -3372.7% | -3179.3% |
| 2020 | -$29M | -34.0% | -$29M | $-6.10 | -6149.7% | -6188.3% |
| 2019 | -$21M | +85.5% | -$23M | $-4.70 | -10050.9% | -10567.3% |
| 2018 | -$148M | -1247.3% | -$148M | $-77.50 | -71826.4% | -71930.3% |
| 2017 | -$11M | -347.3% | -$11M | $-11.62 | -5999.0% | -6271.0% |
| 2016 | -$2M | +92.8% | -$8M | $-3.31 | - | - |
| 2015 | -$34M | -10.3% | -$6M | $-93.02 | - | - |
| 2014 | -$31M | -458.2% | -$3M | $-239.63 | - | - |
| 2013 | -$6M | +5.5% | -$3M | $-584.40 | - | - |
| 2012 | -$6M | -188.7% | -$6M | $-1072.88 | - | - |
| 2011 | -$2M | +60.1% | -$3M | $-529.47 | - | - |
| 2010 | -$5M | -14.1% | -$4M | $-1535.18 | - | - |
| 2009 | -$4M | -103.2% | -$4M | $-1396.11 | - | - |
| 2008 | -$2M | +43.6% | -$2M | $-1124.39 | - | - |
| 2007 | -$4M | -198.4% | -$3M | $-2244.18 | - | - |
| 2006 | -$1M | -31.7% | $-888,000 | $-999999.00 | - | - |
| 2005 | $-990,000 | +63.1% | -$1M | $-989558.00 | - | - |
| 2004 | -$3M | +53.6% | -$3M | $-999999.00 | - | - |
| 2003 | -$6M | -152.9% | -$6M | $-999999.00 | - | - |
| 2002 | -$2M | -493.5% | -$2M | $-999999.00 | - | - |
| 2001 | $-385,000 | +70.2% | $-380,000 | $-384540.00 | - | - |
| 2000 | -$1M | -14.6% | -$1M | $-999999.00 | -4061.0% | -4612.9% |
| 1999 | -$1M | - | -$1M | $-999999.00 | -933.6% | -882.2% |
Download Data
Export MRKR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MRKR — Frequently Asked Questions
Quick answers to the most common questions about buying MRKR stock.
What is MRKR earnings per share (EPS)?
MRKR trailing twelve-month (TTM) diluted EPS is $-0.56, reflecting +33.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Marker Therapeutics, Inc.'s net income?
Marker Therapeutics, Inc. (MRKR) trailing twelve-month net income is $-11M as of 2025. Earnings grew +33.6% year-over-year.
Is MRKR profitable?
MRKR is not currently profitable on a TTM basis, reporting a net loss of $-11M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MRKR's earnings growth rate?
MRKR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are MRKR's profit margins?
Marker Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -0.0%.
Is MRKR growing earnings?
Yes, MRKR earnings are accelerating — EPS growth of +33.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-11M. Earnings momentum is strengthening.
What was MRKR's best earnings year?
Marker Therapeutics, Inc.'s highest annual net income on record is $-385000.00, achieved in fiscal year 2001. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were MRKR's earnings last quarter?
MRKR's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.16. For a full breakdown of all quarters, see the quarterly earnings table on this page.